RT Journal Article
SR Electronic
T1 Patient-reported Outcomes in Polymyalgia Rheumatica
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 795
OP 803
DO 10.3899/jrheum.110977
VO 39
IS 4
A1 ERIC L. MATTESON
A1 HILAL MARADIT-KREMERS
A1 MARCO A. CIMMINO
A1 WOLFGANG A. SCHMIDT
A1 MICHAEL SCHIRMER
A1 CARLO SALVARANI
A1 ARTUR BACHTA
A1 CHRISTIAN DEJACO
A1 CHRISTINA DUFTNER
A1 HANNE SLOTT JENSEN
A1 GYULA POÓR
A1 NOVÁK PÁL KAPOSI
A1 PETER MANDL
A1 PETER V. BALINT
A1 ZSUZSA SCHMIDT
A1 ANNAMARIA IAGNOCCO
A1 FABRIZIO CANTINI
A1 CARLOTTA NANNINI
A1 PIERLUIGI MACCHIONI
A1 NICOLÒ PIPITONE
A1 MONTSERRAT del AMO
A1 GEORGINA ESPÍGOL-FRIGOLÉ
A1 MARIA C. CID
A1 VÍCTOR M. MARTÍNEZ-TABOADA
A1 ELISABETH NORDBORG
A1 HANER DIRESKENELI
A1 SIBEL ZEHRA AYDIN
A1 KHALID AHMED
A1 BRIAN HAZELMAN
A1 COLIN PEASE
A1 RICHARD J. WAKEFIELD
A1 RAASHID LUQMANI
A1 ANDY ABRIL
A1 RALPH MARCUS
A1 NEIL J. GONTER
A1 MEHRDAD MAZ
A1 CYNTHIA S. CROWSON
A1 BHASKAR DASGUPTA
YR 2012
UL http://www.jrheum.org/content/39/4/795.abstract
AB Objective. To prospectively evaluate the disease course and the performance of clinical, patient-reported outcome (PRO) and musculoskeletal ultrasound measures in patients with polymyalgia rheumatica (PMR). Methods. The study population included 85 patients with new-onset PMR who were initially treated with prednisone equivalent dose of 15 mg daily tapered gradually, and followed for 26 weeks. Data collection included physical examination findings, laboratory measures of acute-phase reactants, and PRO measures. Ultrasound evaluation was performed at baseline and Week 26 to assess for features previously reported to be associated with PMR. Response to corticosteroid treatment was defined as 70% improvement in PMR on visual analog scale (VAS). Results. At baseline, 77% had hip pain in addition to shoulder pain and 100% had abnormal C-reactive protein or erythrocyte sedimentation rate. On ultrasound, 84% had shoulder findings and 32% had both shoulder and hip findings. Response to corticosteroid treatment occurred in 73% of patients by Week 4 and was highly correlated with percentage improvement in other VAS measures. Presence of ultrasound findings at baseline predicted response to corticosteroids at 4 weeks. Factor analysis revealed 6 domains that sufficiently represented all the outcome measures: PMR-related pain and physical function, an elevated inflammatory marker, hip pain, global pain, mental function, and morning stiffness. Conclusion. PRO measures and inflammatory markers performed well in assessing disease activity in patients with PMR. A minimum set of outcome measures consisting of PRO measures of pain and function and an inflammatory marker should be used in practice and in clinical trials in PMR.